Repeated intravenous injections in non-human primates demonstrate preclinical safety of an anti-inflammatory phosphorus-based dendrimer

Nanotoxicology

Volumn 9, Issue 4, 2015, Pages 433-441

  Fruchon, Séverine ^a   Mouriot, Sébastien ^b   Thiollier, Thibaud ^b   Grandin, Clément ^b   Caminade, Anne Marie ^c   Turrin, Cédric Olivier ^c   Contamin, Hugues ^b   Poupot, Rémy ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Cynbiose   (France)

^c LCC LABORATOIRE DE CHIMIE DE COORDINATION   (France)

Author keywords

Nanomedicine; Nanotoxicology; Non human primates; Phosphorus based dendrimers; Systemic administration

Indexed keywords

ANTIINFLAMMATORY AGENT; AZABISPHOSPHONIC ACID DERIVATIVE; BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; DENDRIMER; HETEROCYCLIC COMPOUND; UNCLASSIFIED DRUG; PHOSPHORUS;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOCHEMISTRY; BLOOD CLOTTING PARAMETERS; CONTROLLED STUDY; DRUG SAFETY; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; IMMUNOLOGICAL PARAMETERS; MACACA FASCICULARIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ANIMAL; CHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION;

MACACA; PRIMATES;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DENDRIMERS; INJECTIONS, INTRAVENOUS; MACACA FASCICULARIS; MALE; PHOSPHORUS;

EID: 84929752082     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2014.940406     Document Type: Article

References (33)

1. Bonfanti U, Lamparelli D, Colombo P, Bernardi C. 2009. Hematology and serum chemistry parameters in juvenile cynomolgus monkeys (Macaca fascicularis) of Mauritius origin: comparison between purpose-bred and captured animals. J Med Primatol 38:228-35.
2. Bontrop RE. 2001. Non-human primates: essential partners in biomedical research. Immunol Rev 183:5-9.
3. Bosch X. 2011. Dendrimers to treat rheumatoid arthritis. ACS Nano 5: 6779-85.
4. Cohen CR, Brown J, Moscicki AB, Bukisi EA, Paull JR, Price CF, et al. 2011. A phase I randomized placebo controlled trial of the safety of 3% SPL7013 gel (VivaGel-) in healthy young women administered twice daily for 14 days. PLoS One 6:e16258.
5. Colvin VL. 2003. The potential environmental impact of engineered nanomaterials. Nat Biotechnol 21:1166-70.
6. Dobrovolskaia MA, Germolec DR, Weaver JL. 2009. Evaluation of nanoparticle immunotoxicity. Nat Nanotech 4:411-14.
7. Fruchon S, Caminade AM, Abadie C, Davignon JL, Combette JM, Turrin CO, et al. 2013. An azabisphosphonate-capped poly(phosphorhydrazone) dendrimer for the treatment of endotoxin-induced uveitis. Molecules 18:9305-16.
8. Fruchon S, Poupot M, Martinet L, Turrin CO, Majoral JP, Fournié JJ, et al. 2009. Anti-inflammatory and immuno-suppressive activation of human monocytes by a bio-Active dendrimer. J Leukocyte Biol 85: 553-62.
9. Griffe L, Poupot M, Marchand P, Maraval A, Turrin CO, Rolland O, et al. 2007. Multiplication of human natural killer cells by nanosized phosphonate-capped dendrimers. Angew Chem Int Edit 47:2523-6.
10. Hayder M, Fruchon S, Fournié JJ, Poupot M, Poupot R. 2011a. Anti-inflammatory properties of dendrimers per se. Scientific World J 11:1367-82.
11. Hayder M, Poupot M, Baron M, Nigon D, Turrin CO, Caminade AM, et al. 2011b. A phosphorus-based dendrimer targets inflammation and osteoclastogenesis in experimental arthritis. Sci Transl Med 3:81ra35.
12. Heidel JD, Yu Z, Liu YCJ, Rele SM, Liang Y, Zeidan RK, et al. 2007. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci USA 104:5715-21.
13. Hoet PHM, Nemmar A, Nemery B. 2004. Health impact of nanomaterials? Nat Biotechnol 22:104-19.
14. Hunig T. 2012. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol 12:317-18.
15. Jain K, Kesharwani P, Jain NK. 2010. Dendrimer toxicity: lets meet the challenge. Int J Pharm 394:122-42.
16. Lafont BAP, Gloeckler L, DHautcourt JL, Gut JP, Aubertin AM. 2000. One-round determination of seven leukocyte subsets in rhesus macaque blood by flow cytometry. Cytometry 41:193-202.
17. Lappin PB, Black LE. 2003. Immune modulator studies in primates: the utility of flow cytometry and immunohistochemistry in the identification and characterization of immunotoxicity. Toxicol Pathol 31:111-18.
18. Leah E. 2011. Dendrimer drug mends monocytes. Nat Rev Rheumatol 7: 376.
19. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
20. McCarthy TD, Karellas P, Henderson SA, Giannis M, OKeefe DF, Heery G, et al. 2005. Dendrimers as drugs: discovery and preclinical and clinical development of dendrimer-based microbocides for HIV and STI prevention. Mol Pharm 2:312-18.
21. McGowan I, Gomez K, Bruder K, Febo I, Chen BA, Richardson BA, et al. 2011. Phase 1 randomized trial of the vaginal safety and acceptability of SPL7013 gel (VivaGel-) in sexually active young women (MNT-004). AIDS 25:1057-64.
22. Mestas J, Hughes CCW. 2004. Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731-8.
23. Patton DL, Cosgrove Sweeney YT, McCarthy TD, Hillier SL. 2006. Preclinical safety and efficacy assessments of dendrimer-based (SPL7013) microbicide gel formulations in a nonhuman primate model. Antimicrob Agents Chemother 50:1696-700.
24. Portevin D, Poupot M, Rolland O, Turrin CO, Fournié JJ, Majoral JP, et al. 2009. Regulatory activity of azabisphosphonate-capped dendrimers on human CD4+ T cell proliferation enhances ex-vivo expansion of NK cells from PBMCs for immunotherapy. J Transl Med 7:82-94.
25. Poupot M, Griffe L, Marchand P, Maraval A, Rolland O, Martinet L, et al. 2006. Design of phosphorylated dendritic architectures to promote human monocyte activation. FASEB J 20:2339-51.
26. Rolland O, Turrin CO, Caminade AM, Majoral JP. 2009. Dendrimers and nanomedicine: multivalency in action. New J Chem 33:1809-24.
27. Sakurai F, Nakamura S, Akitomo K, Shibata H, Terao K, Kawabata K, et al. 2008. Transduction properties of adenovirus serotype 35 vectors after intravenous administration into nonhuman primates. Mol Ther 16: 726-33.
28. Tarrant J. 2010. Blood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use. Toxicol Sci 117:4-16.
29. Thiagarajan G, Greish K, Ghandehari H. 2013. Charge affects the oral toxicity of poly(amidoamine) dendrimers. Eur J Pharm Biopharm 84: 330-4.
30. Verdier F, Aujoulat M, Condevaux F, Descotes J. 1995. Determination of lymphocyte subsets and cytokine levels in Cynomolgus monkeys. Toxicology 105:81-90.
31. Wagner V, Dullaart A, Bock AK, Zweck A. 2006. The emerging nanomedicine landscape. Nat Biotechnol 24:1211-17.
32. Ye L, Yong KT, Liu L, Roy I, Hu R, Zhu J, et al. 2012. A pilot study in non-human primates shows no adverse response to intravenous injection of quantum dots. Nat Nanotech 7:453-8.
33. Yoshino N, Ami Y, Terao K, Tashiro F, Honda M. 2000. Upgrading of flow cytometry analysis for absolute counts, cytokines and other antigenic molecules of Cynomolgus monkeys (Macaca fascicularis) by using anti-human cross-reactive antibodies. Exp Anim 49:97-110.